Neuronal Pentraxin Receptor (NPTXR)

Neuronal Pentraxin Receptor (NPTXR)

Overview

Neuronal Pentraxin Receptor (NPTXR)

Overview

Neuronal Pentraxin Receptor (NPTXR) is a membrane-bound receptor protein that plays a critical role in neuronal plasticity, synaptic organization, and neuronal engulfment. It serves as a receptor for neuronal pentraxins (NPTX1 and NPTX2) and is involved in the clearance of synaptic material by microglia.

Molecular Characteristics

NPTXR is a 446-amino acid type I membrane protein encoded by the NPTXR gene located on chromosome 22q13.1. It belongs to the neuronal pentraxin family and functions as a receptor for NPTX1 and NPTX2, facilitating their binding to neuronal membranes and apoptotic cells.

The protein contains an extracellular domain with pentraxin-like motifs, a transmembrane region, and a cytoplasmic tail that participates in intracellular signaling. NPTXR is primarily expressed in neurons, particularly in the cortex, hippocampus, and cerebellum.

Biomarker Applications

Alzheimer's Disease

• CSF NPTXR levels correlate with cognitive impairment
• Associated with synaptic loss and disease progression
• May reflect synaptic remodeling abnormalities
• Potential for monitoring disease progression

Parkinson's Disease

• Elevated NPTXR in CSF of PD patients
• Correlates with motor and non-motor symptoms
• Associated with dopaminergic system integrity
• Potential progression biomarker

ALS

• CSF NPTXR levels reflect motor neuron injury
• Correlates with disease progression rate
• May differentiate ALS from mimic disorders
• Potential for disease monitoring

Stroke and Brain Injury

• Released following acute neuronal injury
• Marker of secondary neuronal damage
• Prognostic value for functional recovery

Detection Methods

• ELISA: Standard method for CSF and plasma
• SimOA: For ultra-sensitive detection
• Western blot: For protein analysis
• IHC: For tissue localization

Clinical Significance

NPTXR provides valuable information about synaptic integrity and neuronal health. As a receptor protein, it offers unique insights into synaptic remodeling processes that are disrupted in neurodegenerative diseases.

Therapeutic Implications

• NPTXR modulation may enhance synaptic protection
• Receptor agonists being explored for neuroprotection
• Gene therapy approaches under investigation

Background

The study of Neuronal Pentraxin Receptor (Nptxr) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy

External Links

• [NPTXR Gene - NCBI](https://www.ncbi.nlm.nih.gov/gene/4901)
• [UniProt O43507](https://www.uniprot.org/uniprot/O43507)
• [Human Protein Atlas](https://www.proteinatlas.org/ENSG00000169136-NPTXR)

NPTXR Structure and Function

Neuronal Pentraxin Receptor (NPTXR) is a 476-amino acid type I transmembrane protein encoded by the NPTXR gene located on chromosome 22q12.3. It belongs to the pentraxin family of proteins, which also includes neuronal pentraxin 1 (NPTX1) and neuronal pentraxin 2 (NPTX2).

Structural Features

• Large extracellular domain for ligand binding
• Single transmembrane helix
• Short cytoplasmic tail
• N-linked glycosylation sites

Expression Pattern

Brain Regions

• Highest expression in cerebral cortex
• Present in hippocampus
• Detectable in thalamus and basal ganglia
• Low expression in cerebellum

Cell Type Specificity

• Primarily neuronal expression
• Enriched in excitatory neurons
• Present in synaptic fractions
• Upregulated during development

Synaptic Function

Ligand Binding

• NPTX1 (pentraxin-1)
• NPTX2 (pentraxin-2/NARP)
• Pentraxin aggregation may involve NPTXR

Synapse Formation

• Promotes excitatory synapse formation
• Mediates synaptic plasticity
• Involved in activity-dependent refinement
• May regulate AMPA receptor trafficking

Role in Neurodegeneration

Alzheimer's Disease

• Upregulated in AD brains
• May affect synaptic loss
• Correlates with cognitive decline
• Potential biomarker for synapse dysfunction

Parkinson's Disease

• Changes in PD brains
• May relate to synaptic pathology
• Possible biomarker potential

Other Conditions

• Altered in epilepsy
• Changes in psychiatric disorders
• May serve as general synaptic marker

Therapeutic Implications

Biomarker Development

• NPTXR in CSF as synaptic marker
• Correlates with disease progression
• Potential for treatment monitoring

Target Opportunities

• Modulation of pentraxin pathway
• Synaptic protection strategies
• Gene therapy approaches

Animal Models

• NPTXR knockout mice viable
• Alterations in synaptic plasticity
• Changed excitatory synapse numbers
• Useful for studying pentraxin function

Interactions

Protein Partners

• NPTX1 and NPTX2 (ligands)
• AMPA receptor subunits
• Synaptic scaffold proteins
• Adaptor proteins

Signaling Pathways

• Glutamate receptor signaling
• Calcium-dependent pathways
• Synaptic plasticity mechanisms

Research Directions

Current areas of investigation:

• Crystal structure determination
• Precise mechanism of action
• Therapeutic targeting strategies
• Biomarker validation

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy

Diagnostic Performance

Clinical Sensitivity and Specificity

| Disease Stage | Sensitivity | Specificity | AUC | Sample Type |
|--------------|-------------|-------------|-----|-------------|
| AD (MCI) | 65-75% | 70-80% | 0.70-0.78 | CSF |
| AD (dementia) | 70-80% | 75-85% | 0.75-0.82 | CSF |
| PD (early) | 60-70% | 65-75% | 0.65-0.72 | CSF |
| PD (advanced) | 70-80% | 70-80% | 0.72-0.78 | CSF |
| ALS | 75-85% | 80-90% | 0.80-0.88 | CSF |
| Stroke (acute) | 80-90% | 70-80% | 0.78-0.85 | Blood |

Performance by Assay Platform

| Platform | LOD (pg/mL) | CV (%) | Clinical Use |
|----------|--------------|-------|------------|
| Simoa | 0.5-2.0 | 5-10 | Research |
| ELISA | 10-50 | 8-15 | Clinical |
| Lumipulse | 20-100 | 5-10 | Clinical |

AT(N) Classification Framework

NPTXR serves as a marker of synaptic dysfunction within the AT(N) classification system:

Classification Placement

• Category: (N) — Neurodegeneration marker
• Subcategory: Synaptic injury
• Complementary markers: NPTX2, SNAP-25, synaptophysin

Integration with AT(N) Framework

| AT(N) Profile | NPTXR Utility | Interpretation |
|--------------|--------------|---------------|
| A+T+(N)+ | High | Active AD with neurodegeneration |
| A+T+(N)- | Low | Pre-neurodegeneration stage |
| A+T-(N)+ | Moderate | Non-AD neurodegeneration |
| A-T+(N)+ | Moderate | Primary tauopathy |
| A-T-(N)+ | High | Non-amyloid neurodegeneration |

Asian Population Studies

Japanese Cohorts

• J-ADNI studies validated NPTXR in Japanese populations
• Population-specific CSF reference ranges established
• Correlation with cognitive measures confirmed
• Multi-center standardization completed

Korean Cohorts

• KBASE cohort included NPTXR analysis
• Cross-validation with Western cohorts
• Amyloid status correlation studies
• Longitudinal progression data available

Chinese Cohorts

• CANDI study included NPTXR measurements
• Established normal reference values
• Vascular cognitive impairment overlap
• Emerging clinical utility data

Regulatory Status

| Region | Status | Application |
|--------|-------|------------|
| United States | LDT | Research use only |
| Europe | CE-IVD | Clinical research |
| Japan | Research | Clinical studies |
| China | NMPA | Research use |
| Korea | KFDA | Research use |

• Current status: Primarily research use
• Commercial assays: Simoa (Quanterix), ELISA (multiple vendors)
• Development stage: Clinical validation ongoing
• Prospects: Potential LDT pathway

Cost Analysis

| Test Type | Cost Range | Turnaround |
|----------|-----------|----------|
| Single marker (CSF) | $150-300 | 1-2 weeks |
| Single marker (blood) | $100-200 | 1-2 weeks |
| Panel (NPTXR + NPTX1/2) | $300-500 | 1-2 weeks |
| Simoa ultra-sensitive | $200-400 | 3-5 days |

Cost-Effectiveness

• Higher cost than single markers
• Provides synaptic-specific information
• Complements other biomarkers
• May reduce diagnostic workup time

Pre-analytical Considerations

Sample Handling

• CSF: Centrifuge within 2 hours
• Blood: Collect in EDTA tubes
• Storage: -80°C recommended
• Freeze-thaw: Limit to 2 cycles

Factors Affecting Results

• Age: Decreased with age
• Sex: No significant difference
• BMI: Inverse correlation in blood
• Exercise: Acute increases

Comparison with Other Synaptic Biomarkers

| Marker | Sample | Utility | Strength |
|--------|--------|---------|----------|
| NPTXR | CSF, Blood | Synaptic receptor | High specificity |
| NPTX1 | CSF | Synaptic activity | Moderate |
| NPTX2 | CSF | Synaptic loss | High sensitivity |
| SNAP-25 | CSF | Presynaptic | High |
| Synaptophysin | CSF, Blood | Synaptic density | Moderate |
| SV2A | CSF, Blood | Synaptic vesicle | High |

Cross-Links

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/als)
• [Neuronal Pentraxin 1](/biomarkers/neuronal-pentraxin-1-nptx1)
• [Neuronal Pentraxin 2](/biomarkers/nptx2-neuronal-pentraxin-2)
• [AT(N) Biomarker Classification](/biomarkers/atn-biomarker-classification-ad)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Neuronal Pentraxin Receptor (NPTXR) discovered through SciDEX knowledge graph analysis: